Phathom Pharmaceuticals, Inc. ( (PHAT) ) has released its Q3 earnings. Here is a breakdown of the information Phathom Pharmaceuticals, Inc. presented to its investors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Phathom Pharmaceuticals, Inc., a biopharmaceutical company specializing in gastrointestinal disease treatments, has reported its financial results for the third quarter of 2025, showcasing significant growth and strategic advancements. The company, known for its innovative VOQUEZNA® treatments, continues to strengthen its position in the GI sector.
In the third quarter of 2025, Phathom Pharmaceuticals reported net revenues of $49.5 million, marking a 25% increase from the previous quarter. This growth is attributed to the rising demand for VOQUEZNA prescriptions, which saw a 28% increase from the second quarter. The company has also successfully reduced its cash operating expenses by 43%, reflecting its commitment to financial discipline.
Key highlights from the quarter include the initiation of the Phase 2 pHalcon-EoE-201 trial for VOQUEZNA in treating Eosinophilic Esophagitis and the publication of Phase 3 trial data showing improvements in GERD symptoms. Phathom also strengthened its leadership team with new appointments, enhancing its strategic capabilities. The company has updated its full-year 2025 revenue guidance to $170-$175 million and anticipates achieving operating profitability in 2026.
Looking ahead, Phathom Pharmaceuticals is poised for continued growth, with a focus on expanding its market presence and advancing its clinical trials. The company’s management remains optimistic about its strategic direction and financial outlook, aiming to solidify its leadership in the gastrointestinal treatment market.